166 related articles for article (PubMed ID: 16115720)
1. Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Maniratanachote R; Shibata A; Kaneko S; Yamamori I; Wakasugi T; Sawazaki T; Katoh K; Tokudome S; Nakajima M; Yokoi T
Toxicology; 2005 Dec; 216(1):15-23. PubMed ID: 16115720
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone.
Yokoi T
Handb Exp Pharmacol; 2010; (196):419-35. PubMed ID: 20020270
[TBL] [Abstract][Full Text] [Related]
3. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
Watanabe I; Tomita A; Shimizu M; Sugawara M; Yasumo H; Koishi R; Takahashi T; Miyoshi K; Nakamura K; Izumi T; Matsushita Y; Furukawa H; Haruyama H; Koga T
Clin Pharmacol Ther; 2003 May; 73(5):435-55. PubMed ID: 12732844
[TBL] [Abstract][Full Text] [Related]
4. Autoantibody to aldolase in acute and chronic hepatitis.
Brown C; Toh BH; Pedersen JS; Clarke FM; Mackay IR; Gust I
Pathology; 1987 Oct; 19(4):347-50. PubMed ID: 3328140
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
6. Identification of an anti-aldolase autoantibody as a diagnostic marker for diabetic retinopathy by immunoproteomic analysis.
Ahn BY; Song ES; Cho YJ; Kwon OW; Kim JK; Lee NG
Proteomics; 2006 Feb; 6(4):1200-9. PubMed ID: 16421937
[TBL] [Abstract][Full Text] [Related]
7. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Caldwell SH; Hespenheide EE; von Borstel RW
Dig Dis Sci; 2001 Feb; 46(2):376-8. PubMed ID: 11281188
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
9. Rules and laws of drug hepatotoxicity.
Kaplowitz N
Pharmacoepidemiol Drug Saf; 2006 Apr; 15(4):231-3. PubMed ID: 16552791
[No Abstract] [Full Text] [Related]
10. Second-generation thiazolidinediones and hepatotoxicity.
Marcy TR; Britton ML; Blevins SM
Ann Pharmacother; 2004 Sep; 38(9):1419-23. PubMed ID: 15266041
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
12. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
13. An autopsy case of troglitazone-induced fulminant hepatitis.
Shibuya A; Watanabe M; Fujita Y; Saigenji K; Kuwao S; Takahashi H; Takeuchi H
Diabetes Care; 1998 Dec; 21(12):2140-3. PubMed ID: 9839107
[TBL] [Abstract][Full Text] [Related]
14. Fatal hepatotoxicity associated with troglitazone.
Vella A; de Groen PC; Dinneen SF
Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
[No Abstract] [Full Text] [Related]
15. Troglitazone (Rezulin) and hepatic injury.
Faich GA; Moseley RH
Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
Li H; Heller DS; Leevy CB; Zierer KG; Klein KM
J Diabetes Complications; 2000; 14(3):175-7. PubMed ID: 10989325
[TBL] [Abstract][Full Text] [Related]
17. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Menon KVN ; Angulo P; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1631-4. PubMed ID: 11374713
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effect and side effect of troglitazone].
Toyota T; Ueno Y
Nihon Rinsho; 2000 Feb; 58(2):376-82. PubMed ID: 10707561
[TBL] [Abstract][Full Text] [Related]
19. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
Graham DJ; Drinkard CR; Shatin D
Am J Gastroenterol; 2003 Jan; 98(1):175-9. PubMed ID: 12526954
[TBL] [Abstract][Full Text] [Related]
20. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
Fukano M; Amano S; Sato J; Yamamoto K; Adachi H; Okabe H; Fujiyama Y; Bamba T
Hum Pathol; 2000 Feb; 31(2):250-3. PubMed ID: 10685643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
